The DHDH (dihydrodiol dehydrogenase) antibody is a research tool targeting the DHDH enzyme, a member of the aldo-keto reductase superfamily. DHDH catalyzes the NAD(P)H-dependent oxidation of dihydrodiols, playing roles in xenobiotic metabolism, steroid biosynthesis, and detoxification pathways. It is implicated in the metabolic activation of polycyclic aromatic hydrocarbons (PAHs), linking it to studies on carcinogenesis and environmental toxin processing. DHDH antibodies are primarily used to detect and quantify the enzyme's expression in tissues or cells via techniques like Western blotting, immunohistochemistry, or immunofluorescence. These antibodies aid in exploring DHDH's tissue-specific distribution, regulatory mechanisms, and potential associations with diseases, including cancer and metabolic disorders. Most commercial DHDH antibodies are raised in rabbits or mice using recombinant protein immunogens, with validation focusing on specificity and cross-reactivity controls. Recent studies investigate DHDH's role in drug resistance and its interaction with chemotherapeutic agents, highlighting its therapeutic relevance. However, challenges persist in distinguishing DHDH isoforms due to high sequence homology within the enzyme family. Ongoing research aims to clarify its pathophysiological functions and diagnostic potential.